Equity research analysts tracking Ocugen, Inc. throughout 2026 maintain a consensus "Buy" rating, supported by forward-looking twelve-month price projections that anticipate substantial recovery and growth from its current micro-cap trading levels. Financial forecasts are heavily anchored on clinical trial progression for its flagship ophthalmic programs, regulatory milestones, and disciplined management of operational cash burn. However, individual analyst models remain contingent upon upcoming data readouts and broader macroeconomic sentiment toward high-growth healthcare equities.